JAK-STAT3 signaling occurs during the early adaptive response to EGFR-tyrosine kinase inhibitor (TKI) therapy in EGFR-mutant NSCLC and may occur together with the downstream signaling of NF-κB activation [138]. Here, STAT3 is linked to non-small cell lung carcinoma.